| INTRODUCTION
was preceded by a full-day premeeting on "New Endpoints for NextGeneration Clinical Trials" in which the current and future role of the Banff classification and unmet needs for the field with regard to surrogate endpoints were discussed. In addition, the meeting included as a standing item an update session on the ongoing activities of the Banff
Working Groups, which is summarized in Table 1 .
This meeting report focuses on the main outcomes from the Banff kidney sessions, and the resulting changes to the classification. The main conclusions from the 2017 Banff liver, heart, lung, pancreas, and vascularized composite allograft sessions will be published elsewhere.
The next XV Banff meeting will be held jointly with the American Society of Histocompatibility and Immunogenetics in Pittsburgh, PA, September 23-27, 2019.
| DEFINING ENDPOINTS IN KIDNEY TRANSPLANTATION FOR NEXT-GENERATION CLINICAL TRIALS: PLACE OF THE BANFF SCHEME AND COMBINED ENDPOINTS
The approval of novel drugs in the field of kidney transplantation has been dampened by several factors. One of the explanations for the failure of trials testing new agents has been the success of the "gold standard" immunosuppression demonstrated in the Symphony study and on the other hand, the relative lack of success of new agents. 
K E Y W O R D S
classification systems: Banff classification, kidney transplantation/nephrology, molecular biology, pathology/histopathology, rejection, translational research/science with potentially repositionable drugs known already for their adverse reaction profiles. Acute rejection is also recognized as a primary endpoint for clinical trials in transplantation by health authorities, but TCMR and ABMR do not have the same impact on graft outcome.
Furthermore, the transplant community and the industry aiming to introduce new agents are addressing these issues independently.
The Banff process has evolved from being a primarily pathologydriven group to a more comprehensive and multidisciplinary approach that includes relevant subject matter expertise from immunogeneticists, clinicians, and pathologists with the goal to establish and refine integrative diagnostic standards in transplantation. To accelerate the development of new immunosuppressive agents, Banff is currently working closely with regulatory agencies and international societies to define realistic and feasible endpoints and approaches for next-generation clinical trials. 3, 4 Various specialty societies and consortia have identified the unmet need for the validation of surrogate endpoints in order to evaluate responses to therapy and predict long-term kidney allograft outcomes. During the 2017 Banff premeeting, those new challenges were addressed with a specific focus on histologic, immunologic, and molecular endpoints.
| Histopathology as an endpoint
Rejection episodes confirmed by histology are recognized as the cornerstone of diagnosis and prognosis in kidney and transplantation pathology. However, the current FDA/EMA-approved surrogate histologic endpoint, biopsy-confirmed acute rejection (BCAR), is no longer reflecting current diagnostics in renal transplantation, where the impact of acute TCMR on outcome has declined. As an example, in the BENEFIT Study, BCAR was used as primary endpoint for noninferiority, and there was more BCAR (TCMR) in the arm receiving belatacept (vs cyclosporine), but this did not lead to a higher rate of graft loss in the long term as shown by the BENEFIT-EXT study. 5, 6 To regain usefulness as primary endpoints for trials in kidney transplantation, histologic markers need to follow a validation process as outlined during the Banff meeting (Table 2A) .
| Intragraft gene expression as an endpoint
In Table 2B , we listed our recommendations on best practices for molecular endpoints in clinical trials. Potential diagnostic and prognostic molecular endpoints and biomarkers are listed in Tables 3 and 4 .
| Anti-HLA DSAs as an endpoint
To be a potential surrogate endpoint, anti-HLA DSAs have not only to be considered within the context of their potential limitations (titration rather than mean fluorescence intensity to reveal oversaturation)
but also by integrating their properties (eg, complement activating capacity, IgG subclasses, cytotoxic effect). However, current shortcomings of DSA testing (variability in test methods, diagnostic threshold definitions, clinical significance standards) are known to limit its utility as a sole endpoint. Ongoing efforts of the STAR initiative are aiming to address these.
| Potential of innovative combined endpoints
The participants in the 2017 Banff premeeting support a path toward integrated diagnostic and prognostication systems by exploring opportunities provided by advanced data and applied statistics from the field of machine learning. 7 To this end, the Banff group formed a new working group on surrogate endpoints aimed at fostering collaboration with other professional societies and regulatory agencies on the common goal to develop a path forward to successful nextgeneration multicenter trials and approval of novel drugs in solid organ transplantation.
| 2017 REVISIONS TO THE BANFF CLASSIFICATION

| T cell-mediated rejection
The Banff 2015 meeting report noted for the first time that chronic active TCMR may be manifest in the tubulointerstitial as well as in the vascular compartment. At this point, there is no borderline or suspicious category for chronic active TCMR, particularly as this category within acute TCMR has proved to be troublesome for treating clinicians and even for pathologists to define (see Tables 3 and 4 inflammation, edema, and tubulitis using 3 different histologic stains (hematoxylin and eosin, periodic acid-Schiff, and Masson trichrome).
The silver-stained sections in Figure 1 show tubulitis in mildly to moderately atrophic tubules (best evident in panels B and D), and both of these biopsy specimens also show some severely atrophic tubules. (Table 5) , although this point requires further study, which will be done by the TCMR working group. The interobserver reproducibility of pathologists to distinguish severely atrophic tubules from less atrophic ones will also need further testing, although encouraging results were reported by the Paris group. 8 They reported a complete agreement rate between 3 pathologists of 72% and a κ value of .58 in grading tubulitis in areas of IFTA excluding severely atrophic tubules, although the latter were not defined by a specific reduction in size. active ABMR, chronic active ABMR, and C4d staining without histologic evidence of rejection (Table 5 ). The potentially confusing categories of "suspicious for active ABMR" and "suspicious for chronic active ABMR" are now eliminated. It should be stressed here that these new criteria allowing for the diagnosis of ABMR in the absence of detectable DSAs do not constitute recognition of "antibody-negative ABMR"
| Antibody-mediated rejection
in the sense that Banff 2013 first recognized C4d-negative ABMR. It is rather an acceptance of the fact that current DSA testing methods do not detect all antibodies that are potentially injurious to the allograft, including some non-HLA antibodies, and that using the alternative markers discussed next will allow us to diagnose and treat a small but significant subset of cases of ABMR where current DSA testing methods fall short or are not available. Finally, DSA testing remains strongly recommended in all cases with biopsy specimens meeting the morphologic criteria (criteria 1 and 2) for active or chronic active ABMR (Table 5) , not only for ABMR diagnosis but also for risk stratification, evaluating the response to treatment and further patient monitoring.
A minor consideration in the revised classification, discussed later, involves the removal of the word "acute" from "acute/active ABMR." CAV1  ADAMDEC1  IFNG  BCL2  CITED4  CD244/2B4  A TXN3  ASB15  C OL4A3  A DAMDEC1 ADAM8  IL -10  A POBEC3A  C DH13  ADAMDEC1  PSME2  E VA1C  S1PR1  CD34  AIM2  IL12RB1  C D4  EDA  BCL6  BCL2A1  CHCHD10  C OL4A4  A NKRD22  ANP  I L-1R  C21orf63  CDH5  AIM2  PSTPIP1  F CGR3A  S 1PR5  CD74  ANKRD22  IL18BP  CXCL10  SLC19A3  BTLA  EEF1A1  FJX1  COL4A5  BTLA  BASP1  I L-2RA  C AV1  C OL13A1  ANKRD22  PTPN7  F GFBP2  S DR16C5  CDH13  AOAH  IL21R  C XCL9  SLC22A2  C D57  G EMIN7  K AAG1  EHD3  CD28  Beta-2M  I L-2RB  C CL4  C X3CR1  A OAH  R ARRES3  GNG11  S ELP  CDH5  APOL2  L AG3  G ZMB  S LC25A15  C TLA4  IGLC1  K LH13  NPHS1  C D72  C ASP1  IL10RA  CDH13  D ARC  A POL2  SH2D1A  GNLY  SH2D1B  CX3CR1  BTLA  LAIR1  I L1RL1  S LC4A1  E OMES  MS4A4A  MET  N PHS2  CD8A  CASP3  I L8  CDH5  FGFBP2  BTLA  SIRPG  H EG1  S OX7  CXCL11  CD274  L AP3  I L4  TMEM178  G ATA3  NFKBIA  R NF149  C D96  C ASP4  INDO  CETP  GNG11  C D274  SLA  H SPA12B  TEK  DARC  CD28  LCP2  WARS  TRAF4  IKZF2  R (Table 5) .
We also considered possible molecular alternatives to the DSA criterion. Molecular markers, in the form of those associated with endothelial injury, were first introduced into criterion 2 of the F I G U R E 2 Three renal allograft biopsies specimens showing inflammation in areas of interstitial fibrosis and tubular atrophy (i-IFTA) with varying densities of interstitial fibrosis and degrees of interstitial inflammation, edema, and tubulitis, using 3 different histologic stains. The biopsy specimen in A-C shows dense interstitial fibrosis but also widespread and focally heavy inflammation in the sclerotic interstitium (i-IFTA 3) with tubulitis involving several mildly to moderately atrophic tubules, up to score t3 (arrow, B). The biopsy specimen in D-F also shows dense interstitial fibrosis, but milder inflammation. Although the inflammation in D-F is fairly diffuse, this was not true in other areas of cortex with fibrosis, and the i-IFTA score on this biopsy was 2. In addition, there is only mild tubulitis (t1), and as such, this biopsy specimen did not meet criteria for chronic active T cell-mediated rejection. In the biopsy specimen in G-I, the interstitial fibrosis is focally dense and focally less so with interstitial edema, as is most evident on the trichrome stain in I. There is more variable inflammation (overall i-IFTA score was 2), although t2 tubulitis is evident in a mildly atrophic tubule (arrow, (Table 1) .
| Removal of the term "acute" from "acute/active ABMR"
In Table 2 of the 2013 Banff Classification, 14 it is noted in a footnote that lesions classified as acute/active ABMR may be clinically acute, smoldering, or subclinical; this qualifier was also maintained in the 2015 revision. 1 Thus, the use of the word "acute" in the term "acute/ active ABMR" can be misleading, and it was elected to simply refer to Indicates ≥7 layers in 1 cortical peritubular capillary and ≥5 in 2 additional capillaries, avoiding portions cut tangentially. 4 The clinical significance of these findings may be quite different in grafts exposed to anti-blood group antibodies (ABO-incompatible allografts), where they do not appear to be injurious to the graft and may represent accommodation. However, with anti-HLA antibodies, such lesions may progress to chronic ABMR, and more outcome data are needed.
5
A severely atrophic tubule is defined as one with each of the following 3 features: a diameter <25% of that of unaffected or minimally affected tubules on the biopsy, an undifferentiated-appearing, cuboidal or flattened epithelium, and pronounced wrinkling and/or thickening of the tubular basement membrane.
allograft; smoldering active ABMR, which may be diagnosed on surveillance or indication biopsy specimens in patients who most often have low-level DSAs (de novo or persistent/recurrent); and chronic active ABMR, which most often represents a continuum of the smoldering form should the latter not be diagnosed and treated in a timely manner, frequently in patients with limited compliance. In contrast with true acute ABMR, which can often be reversed by a combination of current, standard-of-care treatments aimed primarily at removing DSAs (eg, plasmapheresis, rituximab, intravenous immunoglobulin), 34, 35 smoldering active ABMR should be a major focus for future clinical trials of novel agents designed to treat active ABMR and prevent de novo or progressing TG by mechanisms other than (or in addition to) DSA removal. In summary, the word "active" in the pathology report indicates ongoing disease activity highlighted by MVI with or without concomitant chronic remodeling (TG, PTCBML, IFTA, cv) of the allograft.
| Recommendations for use of molecular diagnostics
Molecular diagnostics were first introduced into the Banff classification in 2013, 14 although this was limited to ABMR and its introduction was as much to encourage development of more specific and more universally applicable molecular tests as to be used in diagnosing ABMR at that time. That former goal has in fact come to fruition, and multiple groups in North America and Europe are now applying molecular diagnostics in analyzing renal allograft biopsy specimens 18-20 -as summarized in Tables 3 and 4 . Just as the 2013
Banff meeting report 14 put forth recommendations regarding taking a sample of tissue from renal allograft biopsies for electron microscopy (EM) and guidelines for performing EM to detect early changes of transplant glomerulopathy (cg1a), it is now appropriate to recommend sampling of biopsy tissue for molecular studies and to provide guidelines for when such studies are likely to be helpful diagnostically ( ABMR, antibody-mediated rejection; ABO, blood group antigens; cg, Banff chronic glomerulopathy score; DSA, donor-specific antibody; DSAST, donor-specific antibody specific transcript; g, Banff glomerulitis score; MVI, microvascular inflammation; ptc, Banff peritubular capillaritis score; TCMR, T cellmediated rejection; TG, transplant glomerulopathy.
T A B L E 6 Recommended indications for use of molecular diagnostics in renal allograft biopsy diagnosis the thresholds values for chronic active TCMR introduced in this report (Table 5 ).
It should be noted that at this point no specific Banff recommendations are given regarding which molecular classifiers/transcript sets should be tested for or the platform(s) used to assess gene expression.
This includes the decision whether to perform molecular studies on freshly sampled tissue or FFPE, 32,33 the latter having the advantage of being done on the same tissue used for routine histology but with possible reduced sensitivity due to RNA degradation during processing.
In all cases, molecular analyses need to be validated in any individual laboratory performing such testing, and gene expression thresholds significantly associated with ABMR, TCMR, or other lesions may well be different in different laboratories using the same transcript sets and platforms. As mentioned, because there are no specific lesions for ABMR/TCMR, no specific gene would be per se relevant for discrimination these diseases. A holistic molecular approach using machine learning and classifiers has been done in recent years and has provided valuable information for improving the classification and prognostic assessment of rejection. 19, [37] [38] [39] As discussed, the changes made to the Banff classification in 2013 14 stimulated many studies that largely validated those changes but also led to additional modification of the classification presented in the 2015 meeting report 1 and here. Similarly, it is anticipated that the changes and recommendations made in this meeting report will serve as a stimulus for studies testing the validity of the revised diagnostic criteria for TCMR and ABMR with respect to predicting patient outcomes, as well as studies directly applying molecular diagnostics in the clinical setting along the path toward molecular consensus described in the 2015 Banff meeting report.
1
The ultimate goals are not only to improve our ability to predict graft outcomes but also to better guide therapy, including in those cases where histology and serology alone cannot optimally do so, leading to improved patient outcomes compared with the current standard of care.
